Obesity Day: Highlighting the Role of Perivascular Adipose Tissue in Vascular Health
Published in General & Internal Medicine
PVAT is not merely a structural layer surrounding blood vessels; it functions as an active endocrine organ that significantly influences vascular function, inflammation, and metabolic regulation. Growing evidence suggests that PVAT plays a fundamental role in the pathophysiology of obesity-related cardiovascular diseases, necessitating further research and clinical interventions.
The Cardiovascular-Endocrinology Connection
PVAT is a key player in the intersection of endocrinology and cardiovascular health. As an endocrine organ, PVAT secretes a variety of adipokines, including leptin, adiponectin, resistin, and visfatin, which modulate vascular homeostasis, immune responses, and metabolic balance. Dysfunctional PVAT, as seen in obesity, alters these secretions, leading to insulin resistance, increased sympathetic nervous system activity, and systemic inflammation—key drivers of cardiovascular disease. The bidirectional relationship between PVAT and metabolic dysfunction underscores the importance of integrating cardiovascular and endocrine approaches in research and clinical management.
The Significance of PVAT
PVAT secretes bioactive molecules known as adipokines, which regulate vascular tone, immune responses, and inflammation. Under normal physiological conditions, PVAT provides protective effects by releasing anti-inflammatory and vasodilatory factors such as adiponectin and nitric oxide. However, in the presence of obesity, PVAT undergoes pathological changes that contribute to metabolic dysregulation and vascular dysfunction.
The Impact of Obesity on PVAT
Obesity induces PVAT dysfunction, resulting in: 1) Increased infiltration of immune cells, exacerbating vascular inflammation and immune system overactivation. 2) Dysregulated adipokine secretion, leading to a reduction in protective factors such as adiponectin and an increase in pro-inflammatory cytokines. 3) Endothelial dysfunction, contributing to the development of atherosclerosis, hypertension, and reduced vascular compliance. 4) Elevated oxidative stress and lipid imbalances, promoting insulin resistance, type 2 diabetes, and cardiovascular complications. 5) Increased perivascular fibrosis, which impairs normal vessel function and contributes to arterial stiffness and hypertension.
The Importance of Addressing PVAT Dysfunction
Given the rising prevalence of obesity worldwide, understanding PVAT’s role is crucial for developing strategies to combat obesity-related cardiovascular diseases. This issue extends beyond body mass index, emphasizing the impact of adipose tissue behavior on systemic health. Studies have demonstrated that PVAT dysfunction can serve as a biomarker for early cardiovascular disease detection, making it a potential target for preventive and therapeutic strategies.
Potential Interventions
- Lifestyle Modifications: Regular physical activity and a balanced diet have been shown to restore PVAT function, reduce inflammation, and improve metabolic health. Diets rich in omega-3 fatty acids, polyphenols, and fiber have been linked to improved adipose tissue homeostasis and reduced vascular inflammation.
- Pharmacological Strategies: Targeting inflammatory pathways with anti-inflammatory drugs, utilizing insulin-sensitizing agents, and developing novel metabolic therapies may offer promising outcomes in treating PVAT-related diseases. Emerging treatments such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists show potential in mitigating PVAT dysfunction.
- Advancements in Research: Innovative imaging technologies, including magnetic resonance imaging, positron emission tomography/computed tomography scans, and Raman spectroscopy, are providing new insights into PVAT dynamics. These advancements facilitate early detection of PVAT-related vascular pathology and allow for the development of targeted interventions.
- Epigenetic and Molecular Research: Studies suggest that epigenetic modifications in PVAT adipocytes contribute to obesity-induced vascular dysfunction. Exploring these molecular pathways may open new avenues for gene-targeted therapies aimed at reversing adipose tissue dysfunction.
- Surgical and Interventional Approaches: Bariatric surgery has been shown to reduce PVAT mass and improve vascular function. Additionally, novel minimally invasive techniques are being investigated to modify or remove PVAT in patients with severe metabolic complications.
Conclusion
Obesity represents a systemic condition with profound effects on metabolism and vascular health. PVAT is increasingly recognized as a key factor in obesity-related cardiovascular diseases, necessitating further research and targeted interventions. On World Obesity Day 2025, we emphasize the need for interdisciplinary collaboration in developing innovative strategies for improving metabolic and cardiovascular health. Addressing PVAT dysfunction through lifestyle modifications, pharmacological treatments, and advanced imaging techniques may significantly reduce the burden of obesity-related diseases.
References
- Szasz T, Webb RC. Perivascular adipose tissue: more than just structural support. Clin Sci (Lond). 2012;122(1):1-12.
- Antoniades C, Tousoulis D, Vavlukis M, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur Heart J. 2023;44(38):3827-3844.
- Agabiti-Rosei C, Saxton SN, De Ciuceis C, et al. Influence of Perivascular Adipose Tissue on Microcirculation: A Link Between Hypertension and Obesity. Hypertension. 2024;81(1):24-33.
- Queiroz M, Sena CM. Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health. Cardiovasc Diabetol. 2024;23(1):455.
Follow the Topic
-
Cardiovascular Diabetology
This journal considers manuscripts on all aspects of the diabetes/cardiovascular interrelationship and the metabolic syndrome; this includes clinical, genetic, experimental, pharmacological, epidemiological and molecular biology research.
Related Collections
With Collections, you can get published faster and increase your visibility.
Incretin-Based Therapies in Type 2 Diabetes and Obesity: Current Evidence and the Evolving Cardiometabolic Landscape
Cardiovascular Diabetology features a Collection on "Incretin-Based Therapies in Type 2 Diabetes and Obesity: Current Evidence and the Evolving Cardiometabolic Landscape". This is a companion Collection with Cardiovascular Diabetology - Endocrinology Reports with the title "Pleiotropic Actions of Incretin-Based Therapies".
Building upon the growing recognition of cardiometabolic organ protection as a central therapeutic goal, incretin-based therapies have reshaped the management of type 2 diabetes and obesity, extending their clinical relevance far beyond glycemic control. Large-scale cardiovascular outcome trials (CVOTs) have shown that glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE), redefining cardiometabolic risk management and influencing contemporary therapeutic strategies. Targeting the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) pathways, these agents enhance glucose-dependent insulin secretion, promote weight reduction, and exert multi-organ effects. Growing evidence supports their impact on vascular function, myocardial metabolism, renal protection, metabolic dysfunction-associated steatotic liver disease (MASLD), and systemic inflammation.
Three principal pharmacological approaches currently characterize incretin-based therapy:
- GLP-1 receptor agonists (GLP-1RAs), mostly injectable medications with proven improved cardiovascular outcomes and weight-reduction.
- Dual GIP/GLP-1 receptor agonists, newer solely injectable medications designed to enhance glycemic control and weight-reduction efficacy.
- DPP-4 inhibitors (also known as gliptins), oral medications which modestly increase endogenous incretin levels and have no impact on cardiovascular outcomes or body weight.
Beyond glucose lowering, incretin-based therapies are increasingly positioned within the broader cardiometabolic framework, with emerging data supporting cardiovascular and renal protection, as well as effects on endothelial function, atherosclerosis, heart failure phenotypes, and chronic kidney disease progression.
Areas of interest include, but are not limited to:
- Classic antidiabetic, anti-obesity and cardioprotective effects
- Cardiovascular outcomes and mechanistic correlates
- Endothelial and vascular biology
- Myocardial metabolism and heart failure subtypes
- Novel renal and hepatoprotective actions
- Optimization and individualized use of existing GLP-1 receptor agonists
- Development of novel GLP-1 receptor agonists and multi-agonist (dual and triple) strategies
- Emerging extra-metabolic actions, including anti-inflammatory and neuroprotective effects
- Combination therapies, including co-formulations with insulin or SGLT2 inhibitors
- Innovative delivery systems, including non-injectable and implantable approaches
- Real-world comparative effectiveness, long-term safety, adherence and treatment durability
This Collection welcomes original research, translational studies, and comprehensive reviews and meta-analyses that provide novel mechanistic insight or clinically relevant evidence to advance understanding of the expanding role of incretin-based therapies in cardiometabolic medicine.
This Collection supports and amplifies research related to SDG 3, Good Health and Well-Being.
All submissions in this Collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the journal editorial board. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com.
Publishing Model: Open Access
Deadline: Dec 13, 2026
Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Risk Stratification, Prognostic Implications and Therapeutic Innovation
Cardiovascular Diabetology features a Collection on "Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Risk Stratification, Prognostic Implications and Therapeutic Innovation". This is a companion Collection with Cardiovascular Diabetology - Endocrinology Reports with the title "Endocrine Drivers and Clinical Implications of the Cardiovascular–Kidney–Metabolic Syndrome" and with BMC Cardiovascular Disorders with the title "Cardiovascular-Kidney-Metabolic (CKM) Syndrome: diagnosis and management of a systemic disorder".
The cardiovascular–kidney–metabolic (CKM) syndrome describes the multidirectional interactions linking excess adiposity, metabolic dysfunction — particularly insulin resistance and type 2 diabetes — chronic kidney disease, and cardiovascular involvement. In affected individuals, metabolic abnormalities frequently coexist with subclinical or overt cardiovascular disease.
Rather than representing a simple clustering of comorbidities, CKM represents a pathophysiological continuum in which metabolic dysregulation drives progressive cardiovascular and renal injury through inflammation, oxidative stress, renin–angiotensin–aldosterone system activation, lipotoxicity, and endothelial dysfunction, ultimately promoting adverse cardiac remodeling, heart failure, and cardiorenal syndrome.
The American Heart Association has proposed a staged framework ranging from individuals without metabolic risk (stage 0) to isolated adiposity (stage 1), metabolic or kidney disease without overt cardiovascular involvement (stage 2), subclinical cardiovascular disease (stage 3), and symptomatic cardiovascular disease (stage 4). This framework aims to facilitate earlier risk identification and integrated cardiovascular prevention across the CKM spectrum.
Areas of interest include, but are not limited to:
- Early detection of multiorgan abnormalities across CKM stages
- Diagnostic laboratory and imaging biomarkers
- Digital health tools for remote monitoring of blood pressure, weight, glycemia, and kidney function
- Application of explainable artificial intelligence (XAI) for risk prediction and treatment selection
- Geographical epidemiology of CKM syndrome
- Social determinants contributing to CKM development and progression
- Life-course determinants, including childhood obesity and gestational diabetes
- Multi-target non-pharmacological interventions
- Established pharmacological therapies (e.g., SGLT2 inhibitors, GLP-1 receptor agonists, non-steroidal mineralocorticoid receptor antagonists)
- Emerging therapies, including RNA-based approaches, incretin combinations, and anti-inflammatory strategies
This Collection invites original research, systematic reviews, and meta-analyses that contribute to improved risk stratification, prognostic assessment, and therapeutic innovation within the integrated CKM framework.
This Collection supports and amplifies research related to SDG 3, Good Health and Well-Being.
All submissions in this Collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the journal editorial board. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com.
Publishing Model: Open Access
Deadline: Nov 23, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in
On World Obesity Day 2025, it's crucial to recognize the pivotal role of Perivascular Adipose Tissue (PVAT) in obesity-related cardiovascular diseases and its potential as a target for innovative interventions.